II期临床-话题@MedSci

#II期临床#

478篇内容 | 2497人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524949, encodeId=10081524949f1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=55, createdTime=2021-05-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524945, encodeId=39fd152494525, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, objectType=article, longId=210523, objectId=496421052350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=496421052350, replyNumber=0, likeNumber=68, createdTime=2021-04-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=496421052350, moduleTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=496421052350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524944, encodeId=36d0152494475, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, objectType=article, longId=210493, objectId=d849210493a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d849210493a6, replyNumber=0, likeNumber=70, createdTime=2021-04-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d849210493a6, moduleTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d849210493a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524943, encodeId=8ba0152494369, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%, objectType=article, longId=210412, objectId=3592210412ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3592210412ef, replyNumber=0, likeNumber=59, createdTime=2021-04-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3592210412ef, moduleTitle=NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3592210412ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524950, encodeId=be991524950f2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=63, createdTime=2021-04-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524942, encodeId=35e615249426d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, objectType=article, longId=210178, objectId=c5462101e853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5462101e853, replyNumber=0, likeNumber=47, createdTime=2021-04-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5462101e853, moduleTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5462101e853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, objectType=article, longId=209998, objectId=35c620999849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c620999849, replyNumber=0, likeNumber=54, createdTime=2021-04-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c620999849, moduleTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c620999849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524940, encodeId=584e1524940eb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, objectType=article, longId=209884, objectId=8e3c20988469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3c20988469, replyNumber=0, likeNumber=24, createdTime=2021-04-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3c20988469, moduleTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3c20988469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524939, encodeId=354215249392f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=31, createdTime=2021-04-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524938, encodeId=4ca0152493825, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=32, createdTime=2021-04-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524937, encodeId=2d7e152493ea4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, objectType=article, longId=209280, objectId=187220928040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187220928040, replyNumber=0, likeNumber=67, createdTime=2021-04-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187220928040, moduleTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187220928040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524936, encodeId=680d1524936e0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, objectType=article, longId=209159, objectId=3dc92091590c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc92091590c, replyNumber=0, likeNumber=55, createdTime=2021-03-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc92091590c, moduleTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc92091590c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524935, encodeId=517f1524935bc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, objectType=article, longId=209081, objectId=08c1209081f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c1209081f4, replyNumber=0, likeNumber=82, createdTime=2021-03-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c1209081f4, moduleTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08c1209081f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524934, encodeId=48351524934dc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=65, createdTime=2021-03-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=77, createdTime=2021-03-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524932, encodeId=a1cd1524932f9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, objectType=article, longId=208482, objectId=a52b208482ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52b208482ca, replyNumber=0, likeNumber=90, createdTime=2021-03-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52b208482ca, moduleTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52b208482ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524931, encodeId=3ac715249315c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功, objectType=article, longId=208135, objectId=11df20813559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11df20813559, replyNumber=0, likeNumber=90, createdTime=2021-03-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11df20813559, moduleTitle=Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11df20813559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524930, encodeId=b18c152493055, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, objectType=article, longId=207999, objectId=50a420e99915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a420e99915, replyNumber=0, likeNumber=71, createdTime=2021-03-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a420e99915, moduleTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50a420e99915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524929, encodeId=554a1524929c5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, objectType=article, longId=207800, objectId=df3320e8001b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3320e8001b, replyNumber=0, likeNumber=58, createdTime=2021-03-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3320e8001b, moduleTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3320e8001b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524928, encodeId=15f7152492859, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, objectType=article, longId=207665, objectId=541220e665a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541220e665a5, replyNumber=0, likeNumber=82, createdTime=2021-02-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541220e665a5, moduleTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541220e665a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-05-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功

2021-04-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点

2021-04-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%

2021-04-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-04-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验

2021-04-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破

2021-04-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性

2021-04-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2021-04-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-04-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果

2021-04-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始

2021-03-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果

2021-03-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-03-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-03-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点

2021-03-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功

2021-03-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果

2021-03-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

2021-03-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！

2021-02-28

科室
- - 订阅+
  - 更多科室
工具
服务